

# **Influenza A Virus H3N2 Subtype Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Influenza A Virus H3N2 Subtype**

<https://marketpublishers.com/r/I0A546CC7BAEN.html>

Date: September 2018

Pages: 65

Price: US\$ 1,200.00 (Single User License)

ID: I0A546CC7BAEN

## **Abstracts**

Influenza A Virus H3N2 Subtype Infection Drug Development Pipeline Study, H2 2018 is the latest infectious disease publication with comprehensive information of Influenza A Virus H3N2 Subtype Infection pipeline products.

### **DISEASE OVERVIEW**

Influenza A Virus H3N2 Subtype infection is spread through Clostridium tetani bacteria, which is present in the form of spores in the environment and develops as bacteria upon entering into human body. Painful muscle contractions are the primary symptom and the disease is also referred to as 'lockjaw' as jaw muscles are tightened in tetanus infected patient.

Different forms of tetanus include - general, local and cephalic tetanus. Sudden spasms of the vocal cords, fractures, infections, aspiration pneumonia are the major complications of the disease.

Despite low costs of treatment, tetanus is rapidly progressing infectious disease, causing mortality. Fourteen companies are currently developing vaccines and treatment options against tetanus infections. The companies in global tetanus pipeline include - Beijing Minhai Biotechnology Co Ltd, BIKEN Corporation, Biological E Ltd, Cadila Healthcare Ltd, Daiichi Sankyo Company, GC Pharma - Korea, GlaxoSmithKline Plc, Indian Immunologicals Ltd, LG Chem Ltd, Olymvax Biopharmaceuticals Inc, Panacea Biotec Ltd, Sanofi, Serum Institute of India Ltd and Wockhardt Ltd.

## REPORT DESCRIPTION

The Influenza A Virus H3N2 Subtype Infection pipeline guide presents complete overview of drugs currently being developed for Influenza A Virus H3N2 Subtype Infection. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Influenza A Virus H3N2 Subtype Infection pipeline candidate.

Research and Development progress along with latest news related to each of the Influenza A Virus H3N2 Subtype Infection pipeline candidates is included.

Major companies participating in therapeutic development of Influenza A Virus H3N2 Subtype Infection are included in this pipeline report. Company wise pre-clinical and clinical products along with details of drug originator, co-developers/ licensors are provided.

Amid strong interest for cure of Influenza A Virus H3N2 Subtype Infection from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Influenza A Virus H3N2 Subtype Infection clinical and pre-clinical products.

The report assists in identifying potential upcoming companies and drugs in Influenza A Virus H3N2 Subtype Infection pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

## SCOPE OF INFLUENZA A VIRUS H3N2 SUBTYPE INFECTION PIPELINE REPORT INCLUDES

Panorama of Influenza A Virus H3N2 Subtype Infection pipeline markets including statistics on therapeutic drugs and companies involved

Influenza A Virus H3N2 Subtype Infection Pipeline candidates across various development phases including both pre-clinical, discovery and clinical stages are covered

Influenza A Virus H3N2 Subtype Infection pipeline candidates across various 'Mechanism of Actions' are also presented in the study

Overview of companies participating in Influenza A Virus H3N2 Subtype Infection pipeline with short introduction to their businesses and pipeline projects

For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co-developer and licensee are provided.

Research and Development progress and trial details, results wherever available, are also included in the pipeline study

The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Influenza A Virus H3N2 Subtype Infection pipeline therapeutics

## **REASONS TO BUY**

Get clear understanding of the entire Influenza A Virus H3N2 Subtype Infection pipeline, with details on active projects

Get in detail information of each product with updated information on each project along with key milestones

Know the list of companies participating in global Influenza A Virus H3N2 Subtype Infection pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

## Contents

### I. KEY FINDINGS

1. Companies Investing in Influenza A Virus H3N2 Subtype Infection Pipeline include  
Number of Companies with Influenza A Virus H3N2 Subtype Infection projects in pre-clinical Development

Number of Companies with Influenza A Virus H3N2 Subtype Infection projects in Clinical Development

Influenza A Virus H3N2 Subtype Infection Pipeline Companies based in Americas

Influenza A Virus H3N2 Subtype Infection Pipeline Companies based in Europe

Influenza A Virus H3N2 Subtype Infection Pipeline Companies based in Asia Pacific

Influenza A Virus H3N2 Subtype Infection Pipeline Companies based in Rest of the World

2. Pipeline Candidates include

Influenza A Virus H3N2 Subtype Infection Pipeline Agents in Pre-clinical/Discovery stage of Development

Influenza A Virus H3N2 Subtype Infection Pipeline Agents in Clinical Development stage

Influenza A Virus H3N2 Subtype Infection Pipeline Therapeutic Compounds received special status

Mechanism of Action of most pipeline Drugs

Small molecules among the Influenza A Virus H3N2 Subtype Infection Pipeline agents

### II. INSIGHTS INTO INFLUENZA A VIRUS H3N2 SUBTYPE INFECTION PIPELINE

1. Disease Overview

Introduction to Influenza A Virus H3N2 Subtype Infection

Symptoms and Causes of Influenza A Virus H3N2 Subtype Infection

Treatment or Prevention Options for Influenza A Virus H3N2 Subtype Infection

Other Details

2. Phase wise Pipeline Compounds

Influenza A Virus H3N2 Subtype Infection Pipeline Pre-Clinical/Discovery stage Drugs

Influenza A Virus H3N2 Subtype Infection Pipeline Phase 1 stage Drugs

Influenza A Virus H3N2 Subtype Infection Pipeline Phase 2 stage Drugs

Influenza A Virus H3N2 Subtype Infection Pipeline Phase 3 stage Drugs

Influenza A Virus H3N2 Subtype Infection Pipeline Pre-Registration stage Drugs

3. Company wise Influenza A Virus H3N2 Subtype Infection Pipeline Compounds

4. Influenza A Virus H3N2 Subtype Infection Pipeline by Mechanism of Action

### III. INFLUENZA A VIRUS H3N2 SUBTYPE INFECTION PIPELINE COMPOUND DETAILS

CR 8020  
AV5080  
APP-0205  
APP-309  
ARMS-I  
AV5075S  
MD 2009  
M-001  
H3N2 strain A/Udorn/72  
Aspidasept  
CT-P27  
Live-Attenuated influenza Vaccine(LAIV)  
influenza(A/H1N1, A/H3N2, B/Yamagata, and B/Victoria)  
FLU-IGIV  
PN-SIA  
RedeeFlu  
GammaFlu  
BPZE1  
VX-787  
NV-INF-1  
NV-INF-2  
FluCide  
NanoFlu vaccine  
PrEP-001  
H3N2v vaccine  
FLUAD  
H3N2 CVV  
NBP-607  
Tetavalent Influenza vaccine  
Drug Details  
1. Snapshot  
Name of the Therapeutic Agent  
Originator  
Developing Company  
Co-Developer/License Partner

- Orphan Drug/Fast Track/Designation Development Phase
- 2. Drug Overview
- 3. Mechanism of Action
- 4. Current Status
- 5. Clinical Trial Details

#### **IV. INFLUENZA A VIRUS H3N2 SUBTYPE INFECTION PIPELINE COMPANY BRIEFS**

AIMM Therapeutics  
Alla Chem LLC  
Aphios Corp  
Aphios Corp  
ARMS Pharmaceutical LLC  
Asavi Llc  
AusBio Ltd  
BiondVax Pharmaceuticals Ltd  
BioTherapeutics Inc  
Brandenburg Antiinfektiva GmbH  
Celltrion Inc  
Changchun Bcht Biotechnology Co Ltd  
Daiichi Sankyo Co Ltd  
Emergent BioSolutions Inc  
Fides Pharma SPA  
FluGen Inc  
Gamma Vaccines Pty Ltd  
ILiAD Biotechnologies LLC  
Janssen Pharmaceuticals  
NanoViricides Inc  
NanoViricides Inc  
NanoViricides Inc  
Novavax Inc  
PrEP Biopharm Ltd  
Sanofi Pasteur SA  
Seqirus Ltd  
Seqirus Ltd  
SK Chemicals Co Ltd  
Zydus Cadila

## **V. LATEST NEWS AND DEVELOPMENTS IN GLOBAL INFLUENZA A VIRUS H3N2 SUBTYPE INFECTION PIPELINE MARKET**

### **VI. APPENDIX**

1. Publisher's Expertise
2. Research Methodology
3. Contact Information

Some of the sections depicted above may be removed or modified on the basis of information availability

## I would like to order

Product name: Influenza A Virus H3N2 Subtype Infection Drug Pipeline Study, H2 2018- Analysis of Phases, Companies, Mechansim, Trials, Current Status of Pipeline Drugs for Influenza A Virus H3N2 Subtype

Product link: <https://marketpublishers.com/r/I0A546CC7BAEN.html>

Price: US\$ 1,200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I0A546CC7BAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below



and fax the completed form to +44 20 7900 3970